TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20124144

Group type: EXPERIMENTAL
Intervention: Abstinence-only intervention
Number of subjects: 662

Group type: COMPARATOR
Intervention: Control group (health-promotion intervention)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: 8-hour comprehensive intervention
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: 12-hour comprehensive intervention
Number of subjects: 662
Study: 18035192

Group type: EXPERIMENTAL
Intervention: Amlodipine camsylate 5 mg QD for 4 weeks, then increased to 10 mg QD if necessary for 4 weeks
Number of subjects: 189

Group type: COMPARATOR
Intervention: Amlodipine besylate 5 mg QD for 4 weeks, then increased to 10 mg QD if necessary for 4 weeks
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Amlodipine camsylate
Number of subjects: 189

Group type: COMPARATOR
Intervention: Amlodipine besylate
Number of subjects: 189
Study: 16055647

Group type: EXPERIMENTAL
Intervention: Short exposure to subliminally primed concepts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long exposure to subliminally primed concepts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short exposure to descriptively inapplicable trait primes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long exposure to descriptively inapplicable trait primes
Number of subjects: 0
Study: 12189228

Group type: EXPERIMENTAL
Intervention: St. John's wort (900 mg daily, orally for 18 days)
Number of subjects: 5

Group type: COMPARATOR
Intervention: irinotecan alone (without SJW)
Number of subjects: 5
Study: 10449886

Group type: EXPERIMENTAL
Intervention: Progressive systemic sclerosis (PSS) patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 20
Study: 8678247

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study: 2104083

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg t.d.s.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg in the evening) without indomethacin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg in the evening) with concurrent indomethacin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 370586

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (200 mg per kilogram of body weight per day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 64
Study: 31590988

Group type: EXPERIMENTAL
Intervention: Durvalumab plus platinum-etoposide
Number of subjects: 537

Group type: COMPARATOR
Intervention: Platinum-etoposide
Number of subjects: 537
Study: 29471877

Group type: EXPERIMENTAL
Intervention: Personalized intervention based on individual risk for depression, including communication of risk factors and tailored psychosocial program by GPs.
Number of subjects: 3326

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 3326
Study: 27817766

Group type: EXPERIMENTAL
Intervention: Somatostatin (0.25 mg initial dose and 0.25 mg/h for maintenance)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Somatostatin (3.5 μg/(kg·h) continuous intravenous pumping)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Routine postoperative hemostasis (Control group)
Number of subjects: 126
Study: 22879577

Group type: EXPERIMENTAL
Intervention: Executive functioning (EF) remediation training with game elements
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study: 22297610

Group type: EXPERIMENTAL
Intervention: Fatigue of hip flexors/extensors
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fatigue of ankle plantar/dorsiflexors
Number of subjects: 24

Group type: COMPARATOR
Intervention: Visual condition (eyes closed)
Number of subjects: 24
Study: 20738871

Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional process
Number of subjects: 0
Study: 17592905

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic agents (adjunctive treatment)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo (adjunctive treatment)
Number of subjects: 1500
Study: 15976798

Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV) within 6 hours
Number of subjects: 56

Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 56
Study: 12818732

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 25 mg once daily
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 100 mg once daily
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 11119398

Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MDMA (0.5 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dobutamine (20 microg/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dobutamine (40 microg/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8867274

Group type: EXPERIMENTAL
Intervention: Wobenzym (4 x 7 capsules/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diclofenac (2 x 50 mg capsules/day)
Number of subjects: 80
Study: 1729933

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 17201
Study: 3931465

Group type: EXPERIMENTAL
Intervention: Glyburide once daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glyburide twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlorpropamide once daily
Number of subjects: 18
Study: 31278117

Group type: EXPERIMENTAL
Intervention: Whey protein-based nutritional supplement enriched with leucine and vitamin D
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard hospital diet without nutritional support
Number of subjects: 150
Study: 26674360

Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EAC)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 1063
Study: 27769282

Group type: EXPERIMENTAL
Intervention: Blood Pressure Management Application (BPMAP)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 132
Study: 23907291

Group type: EXPERIMENTAL
Intervention: Neoadjuvant single agent doxorubicin
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: PAM50 + CLP
Number of subjects: 94

Group type: COMPARATOR
Intervention: Pathology-based classification
Number of subjects: 94
Study: 22554024

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artesunate-chlorproguanil-dapsone (ASCD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 0
Study: 19196813

Group type: EXPERIMENTAL
Intervention: 60 mg x kg(‐1) human alpha(1)‐AT (Prolastin)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 17893869

Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI)
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI)
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Tailored Intervention plus Phone (TIP)
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1546
Study: 16293984

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (Healthy Volunteers)
Number of subjects: 66
Study: 12439520

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10531891

Group type: EXPERIMENTAL
Intervention: Crisis child care program
Number of subjects: 0
Study: 7772426

Group type: EXPERIMENTAL
Intervention: Nimodipine 15 micrograms kg‐1 h‐1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 micrograms kg‐1 h‐1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nimodipine (both doses)
Number of subjects: 14
Study: 2789070

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg four times daily (9 doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg four times daily with ethamsylate 500 mg before each dose
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 318741

Group type: EXPERIMENTAL
Intervention: Propylic ester of p-hydroxybenzoic acid (PEPH)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31499050

Group type: EXPERIMENTAL
Intervention: Aerobic exercise with blood flow restriction (AE + BFR: 40% VO2max)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE: 80% and 40% VO2max)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aerobic exercise (AE: 40% VO2max)
Number of subjects: 22
Study: 28110112

Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal (IR) added to components of CBT for Insomnia (IR + cCBT-I)
Number of subjects: 94

Group type: COMPARATOR
Intervention: cCBT-I alone
Number of subjects: 94
Study: 25690515

Group type: EXPERIMENTAL
Intervention: Safer-drinking strategies endorsed and implemented (e.g., eating prior to and during drinking, spacing drinks, reducing alcohol consumption)
Number of subjects: 31
Study: 24428305

Group type: COMPARATOR
Intervention: Conventional weight‐based dosing of GH (0.04 mg/kg/day)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: GH dosing titrated to an IGF‐I target of 0 SDS (IGF0T)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: GH dosing titrated to an IGF‐I target of +2 SDS (IGF2T)
Number of subjects: 172
Study: 23097066

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every six months
Number of subjects: 7808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 7808
Study: 19419595

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/d)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-120 mg/d)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg/d)
Number of subjects: 599
Study: 17369558

Group type: EXPERIMENTAL
Intervention: Coach-controlled rehabilitation program
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 241
Study: 15180022

Group type: EXPERIMENTAL
Intervention: neomycin/polymyxin B/hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: ofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: neomycin/polymyxin B
Number of subjects: 0
Study: 11673335

Group type: EXPERIMENTAL
Intervention: Distal-balloon protection system (GuardWire)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No distal protection (Control)
Number of subjects: 76
Study: 9541034

Group type: EXPERIMENTAL
Intervention: Smoked cocaine (up to 405 mg over 5 hours daily) for 4 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Drug-free period (2 days before and after cocaine administration)
Number of subjects: 9
Study: 8017448

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg at bedtime
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 2525415

Group type: EXPERIMENTAL
Intervention: Continuous hepatic artery and intravenous infusion of FUDR (IA/IV group; 21 patients)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hepatic artery infusion alone (IA group; 23 patients)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both IA and IA/IV groups
Number of subjects: 64

Group type: COMPARATOR
Intervention: IA group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IA/IV group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Responders (n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonresponders (n = 32)
Number of subjects: 64
Study: 380735

Group type: EXPERIMENTAL
Intervention: Intrarectal metronidazole given over a 48-hour period before surgery
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 102
Study: 31864674

Group type: EXPERIMENTAL
Intervention: Liver grafts with steatosis
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Liver grafts with high baseline steatosis (> 40%)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Liver grafts with moderate baseline steatosis (20%-39%)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Liver grafts with low baseline steatosis (< 20%)
Number of subjects: 151
Study: 26525562

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2159
Study: 26061874

Group type: EXPERIMENTAL
Intervention: Air-Q
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AmbuAura-i
Number of subjects: 80
Study: 23872647

Group type: EXPERIMENTAL
Intervention: SYNERGY (bioabsorbable polymer everolimus-eluting stent)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: SYNERGY ½ dose
Number of subjects: 291

Group type: COMPARATOR
Intervention: PROMUS Element (durable polymer everolimus-eluting stent)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: SYNERGY
Number of subjects: 291

Group type: COMPARATOR
Intervention: PROMUS Element (PE)
Number of subjects: 291
Study: 21411610

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) ingestion (30 to 80 g/h, not exceeding 8%) during exercise
Number of subjects: 50
Study: 19280938

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 13894

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 13894
Study: 17664405

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg daily
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 15053236

Group type: EXPERIMENTAL
Intervention: Chromogranin A (CgA)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide (PP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combined assessment of CgA and PP
Number of subjects: 68
Study: 10890482

Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microg/kg/min for 24 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 20
Study: 9351079

Group type: EXPERIMENTAL
Intervention: Simvastatin (10mg/day; n = 25)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g/day; n = 18)
Number of subjects: 43
Study: 8095507

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg three times daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nicardipine (30 mg three times daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Esmolol (used for sympathetic blockade)
Number of subjects: 15
Study: 3812100

Group type: EXPERIMENTAL
Intervention: Topical administration of Azatadine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cold, dry air (CDA) exposure
Number of subjects: 16
Study: 11287022

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) hCG administration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intramuscular (IM) hCG administration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both SC and IM hCG administration
Number of subjects: 21
Study: 31160181

Group type: EXPERIMENTAL
Intervention: Humming Crescendo Task (HCT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vowel Crescendo Task (VCT)
Number of subjects: 17
Study: 30808245

Group type: EXPERIMENTAL
Intervention: Low-fat dietary change intervention
Number of subjects: 20180

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20180
Study: 30224390

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (aldesleukin; dose range 0.3-3×10^6 IU)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 25959738

Group type: EXPERIMENTAL
Intervention: Re-adaptation of the dorsolateral peritoneal layer (group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No re-adaptation of the dorsolateral peritoneal layer (group B)
Number of subjects: 200
Study: 24129948

Group type: EXPERIMENTAL
Intervention: VO2peak
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: VO2VT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 39
Study: 22539781

Group type: EXPERIMENTAL
Intervention: Emotion perception training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study: 19934777

Group type: EXPERIMENTAL
Intervention: Nutrafem
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 17581445

Group type: EXPERIMENTAL
Intervention: TF-CBT + sertraline
Number of subjects: 24

Group type: COMPARATOR
Intervention: TF-CBT + placebo
Number of subjects: 24
Study: 15608430

Group type: EXPERIMENTAL
Intervention: Perindopril 2 or 4 mg daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12490338

Group type: EXPERIMENTAL
Intervention: PTSD Checklist (PCL) with a cut score of 30
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: PTSD Checklist (PCL) with a cut score of 45
Number of subjects: 1225
Study: 10458396

Group type: EXPERIMENTAL
Intervention: Topical steroid treatment with improved hygiene
Number of subjects: 318

Group type: COMPARATOR
Intervention: Gentle retraction and personal hygiene (Control)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Buried penis subgroup
Number of subjects: 318
Study: 7822521

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (2.5 mg/kg/day, adjusted to 5.0 mg/kg/day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Etretinate (0.5 mg/kg/day, adjusted to 0.75 mg/kg/day)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cyclosporine replaced by topical dithranol (anthralin)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cyclosporine tapered
Number of subjects: 210

Group type: COMPARATOR
Intervention: Etretinate followed by topical dithranol
Number of subjects: 210
Study: 2358267

Group type: EXPERIMENTAL
Intervention: Nitrogen cooled cryoprobe
Number of subjects: 15

Group type: COMPARATOR
Intervention: CO2‐cooled cryoprobe
Number of subjects: 15
Study: 347990

Group type: EXPERIMENTAL
Intervention: Sch 1000 aerosol
Number of subjects: 23
Study: 30746642

Group type: EXPERIMENTAL
Intervention: Pre-Visit Prioritization email intervention
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1276
Study: 27015911

Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Seed Oil with Natural Antioxidants (SOP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sunflower Oil (SFO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mixed Seed Oil with Added Dimethylpolysiloxane (SOX)
Number of subjects: 20
Study: 25819853

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 months
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Dose-adjusted vitamin K antagonist (VKA) once daily
Number of subjects: 2100
Study: 24083174

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ischemic heart disease (IHD)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Non-proliferative diabetic retinopathy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 123
Study: 21306433

Group type: EXPERIMENTAL
Intervention: Sphincter of Oddi (SO) manometry by choledochoscope
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 51
Study: 19899575

Group type: EXPERIMENTAL
Intervention: Standard coaxial phacoemulsification
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microincisional cataract surgery (MICS)
Number of subjects: 30
Study: 18210897

Group type: EXPERIMENTAL
Intervention: Estrogen-only
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 59

Group type: COMPARATOR
Intervention: Calcium-only
Number of subjects: 59
Study: 15551207

Group type: EXPERIMENTAL
Intervention: Combination vaccine (RSV cpts‐248/404 and PIV3‐cp45), 10(5) plaque‐forming units of each per 0.5‐mL dose
Number of subjects: 33

Group type: COMPARATOR
Intervention: Monovalent PIV3 vaccine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Monovalent RSV cpts‐248/404 vaccine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both vaccines (combination and monovalent)
Number of subjects: 33
Study: 11213068

Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 9407422

Group type: EXPERIMENTAL
Intervention: Lowest tertile of baseline proteinuria (< 2.5 g/24 hr)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Middle tertile of baseline proteinuria (2.5 to 4.3 g/24 hr)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Highest tertile of baseline proteinuria (> 4.3 g/24 hr)
Number of subjects: 274
Study: 8504651

Group type: EXPERIMENTAL
Intervention: Aminophylline (4 mg/kg bolus followed by 2.5 mg/kg every 6 hrs x three doses, then 1.5 mg/kg every 6 hrs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2890820

Group type: EXPERIMENTAL
Intervention: Sleeping with the bed-head raised
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ranitidine therapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combination of sleeping with the bed-head raised and ranitidine therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 29016543

Group type: EXPERIMENTAL
Intervention: 33-gauge needle
Number of subjects: 318

Group type: COMPARATOR
Intervention: 30-gauge needle
Number of subjects: 318
Study: 26614597

Group type: EXPERIMENTAL
Intervention: ibandronate 1 mg/month
Number of subjects: 1134

Group type: COMPARATOR
Intervention: risedronate oral 2.5 mg/day
Number of subjects: 1134
Study: 26775516

Group type: EXPERIMENTAL
Intervention: Leg ergometry exercise of 80% peak Watt for 30 minutes per day, 3 days per week for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group without exercise
Number of subjects: 30